Saturday 17 October 2026
Export ZYBT’s income statement to Excel — free account
Zhengye Biotechnology Holding Limited
ZYBT Healthcare Drug Manufacturers Specialty & Generic
Zhengye Biotechnology Holding Limited’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, down 34.8% from fiscal 2024.
1.43
0.07
−4.67%
Follow ZYBT
| Older periods | Jun '24 | Dec '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
|
+1 more TTM period Free account |
— | — | — | 0.00% | |
| — | — | — | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | — | 0.00 | 0.00 | |
Free Cash Flow |
— | — | 9.33 | 5.34 | |
Capital Expenditures |
— | — | (3.00) | (2.27) | |
| Other line items | |||||
Cash ROIC |
0.00% | 0.00% | 13.41% | 8.62% | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | — | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.29 | 0.20 | |
Capex/Depreciation |
— | — | (0.30) | (0.22) | |
Operating CF per Share |
— | — | 0.00 | 0.00 | |
Capex per Share |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates